ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

ClinicalTrials.gov ID: NCT01667419

Public ClinicalTrials.gov record NCT01667419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence

Study identification

NCT ID
NCT01667419
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
498 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Drug
  • Vemurafenib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 23, 2012
Primary completion
Jun 22, 2017
Completion
Jul 12, 2018
Last update posted
Jul 22, 2019

2012 – 2018

United States locations

U.S. sites
47
U.S. states
17
U.S. cities
41
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294
UCLA Department of Medicine; Division of Hematology / Oncology California City California 90095
Kaiser Permanente - Hayward Hayward California 94545
UCLA Hematology Oncology - Irvine Irvine California 92604
UCSD Moores Cancer Center La Jolla California 92093
The Angeles Clinic and Research Institute - W LA Office Los Angeles California 90025
Cancer Center Of Santa Barbara; Network Clinical Research Specialist Los Angeles California 90095
TRIO-US Network Administration; Network Clinical Research Specialist Los Angeles California 90095
Kaiser Foundation Hospital - Oakland (W. MacArthur) Oakland California 94611
Kaiser Permanente - Oakland Oakland California 94611
UCLA Healthcare/Pasadena Oncology Pasadena California 91105
Kaiser Permanente - Roseville Roseville California 95661
Kaiser Permanente Sacramento Medical Center Sacramento California 95814
Kaiser Permanente San Francisco California 94115
K. Permanente - San Jose San Jose California 95119
Coastal Integrative Cancer Care San Luis Obispo California 93401
Kaiser Permanente - Santa Clara Santa Clara California 95051
Kaiser Permanente - South San Francisco South San Francisco California 94080
Stanford University School of Medicine; Stanford Hospital Pharmacy Stanford California 94305
UCLA Cancer Center Hema/Oncol Valencia California 91355
Kaiser Permanente - Vallejo Vallejo California 94589
Kaiser Permanente - Walnut Creek Walnut Creek California 94596
UCLA Hematology Oncology - Westlake Westlake Village California 91361
University Of Colorado Aurora Colorado 80045
St. Mary's Hospital Regional Cancer Center Grand Junction Colorado 81501
Florida Cancer Specialists - Broadway Fort Myers Florida 33901
Memorial Healthcare System Hollywood Florida 33021
GulfCoast Oncology Sarasota Florida 34232
Oncology Specialists, S.C. Park Ridge Illinois 60068
Indiana University Health; Goshen Center for Cancer Care Goshen Indiana 46526
Indiana University Department of Medicine; Division of Infectious Diseases Indianapolis Indiana 46202
U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology Louisville Kentucky 40202
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201
St. Luke's Hospital Kansas City Missouri 64111
University of Kansas Medical Center; Cancer Center Kansas City Missouri 64131
Washington University; Dept of Medicine/Div of Medical Oncology St Louis Missouri 63110
Atlantic Health Systems; Pediatrics Randolph Township New Jersey 07869
New York University Medical Center PRIME; NYU Clinical Cancer Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10065
Duke University Medical Center; Oncology Durham North Carolina 27710
University of Pennsylvania Health System Philadelphia Pennsylvania 19104
MUSC Hollings Cancer Center/cannon Park Place; Attn: Tamara Saunders Charleston South Carolina 29425
West Clinic Germantown Tennessee 38138
Tennessee Oncology PLLC - Nashville (20th Ave) Nashville Tennessee 37203
Vanderbilt University Medical Center Nashville Tennessee 37232
MD Anderson Cancer Center Houston Texas 77030
Mary Babb Randolph Cancer Center Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 160 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01667419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 22, 2019 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01667419 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →